Viking Therapeutics (VKTX) COO discloses new equity grants and tax-related share sales
Rhea-AI Filing Summary
Viking Therapeutics reported insider equity activity by its Chief Operating Officer. On January 2, 2026, the officer received 41,000 restricted stock units and an additional 32,049 shares from performance-based restricted stock units, both at $0 cost, increasing beneficial ownership. On the same date, the officer was also granted a stock option for 91,000 shares at an exercise price of $35.42 per share, vesting in equal annual installments over four years. On January 5, 2026, a total of 57,661 shares were automatically sold in multiple transactions at weighted-average prices between about $31.87 and $35.20 to cover tax withholding obligations tied to these vesting awards. Following these transactions, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.00001 per share | 31,961 | $32.2928 | $1.03M |
| Sale | Common Stock, par value $0.00001 per share | 13,600 | $33.3732 | $454K |
| Sale | Common Stock, par value $0.00001 per share | 10,500 | $34.2193 | $359K |
| Sale | Common Stock, par value $0.00001 per share | 1,600 | $35.0731 | $56K |
| Grant/Award | Stock Option (Right to Buy) | 91,000 | $0.00 | -- |
| Grant/Award | Common Stock, par value $0.00001 per share | 41,000 | $0.00 | -- |
| Grant/Award | Common Stock, par value $0.00001 per share | 32,049 | $0.00 | -- |
Footnotes (1)
- Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 108 shares acquired on May 20, 2025 and 116 shares acquired on November 20, 2025 both pursuant to the Issuer's 2024 Employee Stock Purchase Plan. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the option will vest on each anniversary of the grant date.
FAQ
What insider transactions were reported for Viking Therapeutics (VKTX)?
The Chief Operating Officer of Viking Therapeutics reported multiple equity transactions, including grants of restricted stock units, vesting of performance-based awards, a new stock option grant, and automatic share sales to cover tax withholding obligations.
What stock option grant was reported for the Viking Therapeutics (VKTX) officer?
The officer received a stock option covering 91,000 shares of Viking Therapeutics common stock with an exercise price of $35.42 per share. According to the disclosure, 25% of the shares under the option vest on each anniversary of the January 2, 2026 grant date.
What vesting terms apply to the Viking Therapeutics (VKTX) RSU and option awards?
The 41,000-share RSU award vests one-third on each one-year anniversary of the grant date. The stock option for 91,000 shares vests 25% on each anniversary of the grant date, and the performance RSUs vested based on achievement of specified non-financial performance goals.